Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $58.00 price target on the stock.
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million